PepGen (PEPG) Non-Current Assets (2021 - 2026)
PepGen (PEPG) posted Non-Current Assets of $22.0 million for Q1 2026, down 4.01% sequentially from $22.9 million in Q4 2025, and down 16.4% YoY from $26.3 million in Q1 2025.
Analysis
PepGen (PEPG) Non-Current Assets (2021 - 2026) Analysis & Trends
PepGen has reported Non-Current Assets for 6 years, with the latest figure at $22.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 16.4% year-over-year to $22.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.6 million (down 14.98% YoY) and the FY2025 annual result came in at $22.9 million, down 15.4% from the prior year.
- Non-Current Assets eased to $22.0 million in Q1 2026 per PEPG's latest filing, from $22.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $32.6 million in Q1 2023 and troughed at $4.2 million in Q3 2022.
- A 5-year average of $23.8 million and a median of $27.1 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 757.92% in 2022, then decreased 16.4% in 2026.
- Over 5 years, Non-Current Assets stood at $31.4 million in 2022, then retreated by 3.13% to $30.4 million in 2023, then slipped by 10.71% to $27.1 million in 2024, then declined by 15.4% to $22.9 million in 2025, then dropped by 4.01% to $22.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $22.0 million, $22.9 million, and $23.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 21.07 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.07 Mn |
| Mar 31, 2026 | 22.02 Mn |
| Dec 31, 2025 | 22.94 Mn |
| Sep 30, 2025 | 23.85 Mn |
| Jun 30, 2025 | 24.76 Mn |
| Mar 31, 2025 | 26.35 Mn |
| Dec 31, 2024 | 27.12 Mn |
| Sep 30, 2024 | 27.87 Mn |
| Jun 30, 2024 | 28.73 Mn |
| Mar 31, 2024 | 29.38 Mn |
| Dec 31, 2023 | 30.37 Mn |
| Sep 30, 2023 | 31.18 Mn |
| Jun 30, 2023 | 31.71 Mn |
| Mar 31, 2023 | 32.57 Mn |
| Dec 31, 2022 | 31.36 Mn |
| Sep 30, 2022 | 4.21 Mn |
| Jun 30, 2022 | 4.32 Mn |
| Mar 31, 2022 | 6.21 Mn |
| Dec 31, 2021 | 3.66 Mn |